{
    "organizations": [],
    "uuid": "84b28cb4ef29cad3d30cdd585e78f5c9336c5f0c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-to-present/brief-eleven-biotherapeutics-to-present-early-data-from-bladder-cancer-trial-in-may-idUSASC09UOZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Eleven Biotherapeutics To Present Early Data From Bladder Cancer Trial In May",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Eleven Biotherapeutics Inc:\n* PRELIMINARY DATA FROM PHASE 3 VISTA TRIAL IN BLADDER CANCER TO BE PRESENTED IN A PLENARY SESSION AT AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING\n* ELEVEN BIOTHERAPEUTICS-WITHIN SUBGROUP OF FIRST 75 EVALUABLE PATIENTS, PRELIM FINDINGS SHOW OVER 95 PCT EXPRESSED EPCAM ON SURFACE OF TUMOR CELLS​\n* ELEVEN BIOTHERAPEUTICS INC - ‍VICINIUM HAS BEEN WELL-TOLERATED​​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T21:01:00.000+03:00",
    "crawled": "2018-04-04T12:42:34.040+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "eleven",
        "biotherapeutics",
        "inc",
        "preliminary",
        "data",
        "phase",
        "vista",
        "trial",
        "bladder",
        "cancer",
        "presented",
        "plenary",
        "session",
        "american",
        "urological",
        "association",
        "annual",
        "meeting",
        "eleven",
        "subgroup",
        "first",
        "evaluable",
        "patient",
        "prelim",
        "finding",
        "show",
        "pct",
        "expressed",
        "epcam",
        "surface",
        "tumor",
        "eleven",
        "biotherapeutics",
        "inc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}